Status:
COMPLETED
Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study
Lead Sponsor:
GlaxoSmithKline
Conditions:
Cognitive Disorders
Eligibility:
MALE
35-55 years
Phase:
PHASE1
Brief Summary
GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men to investigate how much of the study ...
Detailed Description
This is an open label, single dose, non-randomized PET study in healthy male subjects to ascertain if GSK1034702 is crossing the blood-brain barrier to enable it to elicit a central effect. GSK1034702...
Eligibility Criteria
Inclusion
- Generally healthy.
- Male between 35 and 55 years of age.
- Willing to use appropriate contraception method.
- Weight more than 50 kg.
- BMI within the range 19 - 29 kg/m2.
- Adequate blood supply to the hand.
Exclusion
- Abuse of drugs or alcohol.
- Smoker or history of regular use of tobacco- or nicotine-containing products in the past 6 months.
- ECG abnormality (personal or family history).
- Psychiatric disorder.
- Asthma or a history of asthma.
- Medical illness.
- Worked as a welder, metal worker or machinist.
- Suffers from claustrophobia or would be unable to lie still in a PET or MRI scanner for 1-2 hours.
- Has a cardiac pacemaker or other electrical device or ferromagnetic metal foreign bodies.
- Neurological disorder
Key Trial Info
Start Date :
July 15 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 28 2009
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00937846
Start Date
July 15 2009
End Date
August 28 2009
Last Update
June 27 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
London, United Kingdom, NW10 7EW
2
GSK Investigational Site
London, United Kingdom, W12 ONN